티스토리

Real world embedding
검색하기

블로그 홈

Real world embedding

real-world-embedding.tistory.com/m

I write daily about pharmacology, machine learning, clinical trials, and so on a daily basis.

구독자
1
방명록 방문하기
공지 데이터 요청 관련 문의 모두보기

주요 글 목록

  • Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Highlights Advancements of Akston Biosciences' Ambifect® Fc-fusion Platform Publication of AKS-452 Phase II Vaccine Study Results in Nature Vaccines Overview Company: Akston Biosciences Indication: SARS-CoV-2 Vaccination Drug: AKS-452 Trial Phase: Phase 2 NCT ID: N/A Study Results Akston Biosciences has published the results of their Phase II clinical trial for the AKS-452 vaccine in Nature Vaccines. This study, conducted in the Netherlands, aimed to boost the immune re.. 공감수 1 댓글수 0 2024. 2. 28.
  • Harvard Gastroenterology Specialist Dr. Hamed Khalili Appointed to Vivante Health Clinical Advisory Board for Inflammatory Bowel Disease Research Harvard Gastroenterology Specialist Dr. Hamed Khalili Joins Vivante Health Advisory Board Overview Company: Vivante Health Indication: Inflammatory Bowel Diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details Vivante Health has appointed Dr. Hamed Khalili to its Clinical Advisory Board to advance research in inflammatory bowel diseases. Dr. Khalili is a respected gastroenterologist at Massachus.. 공감수 0 댓글수 0 2024. 2. 28.
  • Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations Initiation of KOMET-008 Phase 1 Clinical Trial by Kura Oncology with Ziftomenib and Standard Care Combinations for Acute Myeloid Leukemia Patients with Specific Genetic Alterations Overview Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemia (AML) Drug: Ziftomenib Trial Phase: Phase 1 NCT ID: NCT06001788 Introduction On February 26, 2024, Kura Oncology, Inc., a company at the forefro.. 공감수 0 댓글수 0 2024. 2. 28.
  • MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA MoonLake Immunotherapeutics Receives Unanimous Support for Phase 3 Trial of Sonelokimab in Hidradenitis Suppurativa from FDA and EMA Company: MoonLake Immunotherapeutics Indication: Hidradenitis Suppurativa (HS) Drug: Sonelokimab (SLK) Trial Phase: Phase 3 NCT ID: NCT05322473 Overview MoonLake Immunotherapeutics, a clinically-focused biopharmaceutical company, has announced a significant milesto.. 공감수 0 댓글수 0 2024. 2. 28.
  • BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062, Aiming to Target CKD and Proteinuria BioCity Biopharma Completes Enrollment for IgA Nephropathy Cohort in Phase II Trial of SC0062 Company: BioCity Biopharma Indication: IgA nephropathy (IgAN), chronic kidney disease (CKD), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: Not provided Overview BioCity Biopharma has announced the successful completion of patient enrollment for the IgA nephropathy (IgAN) cohort.. 공감수 0 댓글수 0 2024. 2. 28.
  • Enhanced Risk Stratification in Stage I Melanoma Patients Achieved Using DecisionDx-Melanoma Test Over Traditional AJCC8 Methodology Enhanced Risk Stratification in Stage I Melanoma Patients Using DecisionDx-Melanoma Overview Company: Castle Biosciences, Inc. Indication: Stage I Cutaneous Melanoma (CM) Drug/test: DecisionDx-Melanoma Test Trial Phase: Not Applicable NCT ID: Not Available Background Castle Biosciences, Inc. announced on February 26, 2024, a significant enhancement in risk stratification for Stage I Cutaneous Me.. 공감수 0 댓글수 0 2024. 2. 28.
  • Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Preliminary Results Display Full Tumor Eradication in Non-surgical Breast Cancer Patients Using IceCure's ProSense® Cryoablation Therapy Overview Company: IceCure Medical Ltd. Indication: Early-Stage Breast Cancer Drug/Treatment: ProSense® System Trial Phase: Not applicable NCT ID: Not available Study Summary In a groundbreaking study led by Dr. Federica di Naro at Azienda Ospedaliero-Universita.. 공감수 0 댓글수 0 2024. 2. 28.
  • NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering NewBiologix Engages with Florabio to Transform Gene Therapy Manufacturing through Advanced HEK293 Cell Line Engineering Company: NewBiologix SA Indication: Not Applicable Drug: Recombinant adeno-associated virus (rAAV) vectors Trial Phase: Not Applicable NCT ID: Not Available Overview On February 27, 2024, NewBiologix SA, a biotech firm based in Lausanne, Switzerland, announced a strategic partn.. 공감수 0 댓글수 0 2024. 2. 28.
  • Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children Akili and Shionogi Declare Success in Phase 3 Clinical Trial for EndeavorRx as ADHD Treatment for Japanese Children Overview Company: Akili, Inc. & Shionogi & Co. Ltd Indication: Pediatric ADHD Drug: SDT-001 (localized version of AKL-T01 / EndeavorRx) Trial Phase: Phase 3 NCT ID: N/A Akili, Inc., in collaboration with Shionogi & Co. Ltd, announced the successful completion of a Phase 3 clinical .. 공감수 0 댓글수 0 2024. 2. 28.
  • Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Bitterroot Bio and Biotheus Forge Partnership for Bispecific Protein Development in Cardiovascular Immunotherapy Overview Company: Bitterroot Bio; Biotheus Indication: Cardiovascular diseases Drug: N/A Trial Phase: N/A NCT ID: N/A Details In a significant stride within the field of cardio-immunology, Bitterroot Bio and Biotheus have publicly announced the establishment of a multi-year research c.. 공감수 0 댓글수 0 2024. 2. 28.
  • CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk Non-Muscle Invasive Bladder Cancer CG Oncology Initiates PIVOT-006 Phase 3 Trial for Cretostimogene Targeting Intermediate-risk NMIBC Overview Company: CG Oncology, Inc. Indication: Intermediate-risk Non-Muscle Invasive Bladder Cancer (NMIBC) Drug: Cretostimogene Trial Phase: Phase 3 NCT ID: NCT06111235 Trial Details On February 27, 2024, CG Oncology announced the commencement of their Phase 3 PIVOT-006 clinical trial. This pivot.. 공감수 0 댓글수 0 2024. 2. 28.
  • Recce Pharmaceuticals Furthers Ongoing Phase I/II Clinical Trial of RECCE® 327 Targeting Diabetic Foot Ulcer Infections with Expanded Patient Recruitment Overview Company: Recce Pharmaceuticals Ltd Indication: Diabetic Foot Infections Drug: RECCE® 327 Trial Phase: Phase 1/2 NCT ID: N/A Trial Expansion Announcement Recce Pharmaceuticals Ltd has expanded the patient recruitment for their ongoing Phase I/II clinical trial evaluating the synthetic anti-infective agent, RECCE® 327, for the treatment of Diabetic Foot Ulcer Infections. Background Diabet.. 공감수 0 댓글수 0 2024. 2. 28.
  • Tonix Pharmaceuticals Reveals Promising Pharmacokinetics of Cyclobenzaprine for Fibromyalgia in Japan and China Tonix Pharmaceuticals Reveals Promising Pharmacokinetics of Cyclobenzaprine for Fibromyalgia in Japan and China Company: Tonix Pharmaceuticals, Inc. Indication: Fibromyalgia Drug: Tonmya™ (TNX-102 SL, cyclobenzaprine HCl sublingual tablets) Trial Phase: Phase 3 NCT ID: N/A Overview Tonix Pharmaceuticals, Inc., a pioneering biopharmaceutical company, disclosed favorable outcomes from its pharmaco.. 공감수 0 댓글수 0 2024. 2. 28.
  • Phylos and People Science Reveal Clinical Study Outcomes Demonstrating the Stimulating Impact of Tetrahydrocannabivarin (THCV) on Energy Levels Pharmacological News: THCV's Energizing Impact Overview Company: Phylos Indication: Energizing Effects Drug: Natural Natural THCV Trial Phase: N/A NCT ID: Not applicable Study Findings Phylos, a cannabis genetics company, along with People Science, has conducted an IRB-endorsed clinical study on THCV’s energizing effects. The study was placebo-controlled and double-blind and showed that Natural .. 공감수 0 댓글수 0 2024. 2. 28.
  • Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension Third Pole Therapeutics Triumphs with eNOfit™ System EFS for Non-Hospital Treatment of Pulmonary Hypertension Overview Company: Third Pole Therapeutics Indication: Pulmonary hypertension associated with Interstitial Lung Disease (ILD) Drug: eNOfit™ (Inhaled Nitric Oxide Delivery System) Trial Phase: N/A NCT ID: Not available Early Feasibility Study (EFS) Success Third Pole Therapeutics, a forefr.. 공감수 0 댓글수 0 2024. 2. 28.
  • Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines Baseimmune Secures $11.3 Million Series A Investment for Accelerated Development of AI-Designed Cross-Protective Vaccines Company: Baseimmune Indication: - African swine fever - Coronavirus - Malaria Drug: AI-designed cross-protective vaccine candidates Trial Phase: N/A NCT ID: N/A Overview Baseimmune is a biotechnological firm committed to leading vaccine innovation using a proprietary artifici.. 공감수 1 댓글수 0 2024. 2. 27.
  • PolarityTE Commences Phase III Trial for SkinTE in Diabetic Foot Ulcers PolarityTE Commences Phase III Trial for SkinTE in Diabetic Foot Ulcers Overview Company: PolarityTE Indication: Diabetic foot ulcers Drug: SkinTE Trial Phase: Phase 3 NCT ID: Not provided PolarityTE has initiated the first subject screening for their Phase III pivotal study, entitled 'COVER DFUS II', which investigates the use of their novel product SkinTE for the treatment of Wagner grade 1 di.. 공감수 0 댓글수 0 2024. 2. 27.
  • Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Hoth Therapeutics Advances Preclinical Development of HT-KIT With Altasciences Collaboration for Mast Cell-Derived Cancer Treatment Overview Company: Hoth Therapeutics, Inc. Indication: Mast Cell-Derived Cancers Drug: HT-KIT Trial Phase: Preclinical (N/A for IND-enabling studies) Nct ID: Not applicable Development Update Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, has a.. 공감수 0 댓글수 0 2024. 2. 27.
  • Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients Commencement of the CONVERT II Pivotal Trial for AeriSeal® System: A Landmark Study by Pulmonx Corporation Aiming to Treat Severe COPD/Emphysema Patients Overview Company: Pulmonx Corporation Indication: Chronic Obstructive Pulmonary Disease (COPD)/Emphysema Drug: AeriSeal® System followed by Zephyr® Valves Trial Phase: N/A NCT ID: NCT06035120 Trial Initiation Details Pulmonx Corporation, a glob.. 공감수 0 댓글수 0 2024. 2. 27.
  • Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Advancement in Acute Myeloid Leukemia Treatment: Kura Oncology Initiates Phase 1 KOMET-008 Trial with Ziftomenib in Combination Therapies Overview Kura Oncology, Inc., a company leading the way in precision medicine for cancer, has begun a promising new clinical trial for Acute Myeloid Leukemia (AML) treatment. Clinical Trial Details Company: Kura Oncology, Inc. Indication: Acute Myeloid Leukemi.. 공감수 0 댓글수 0 2024. 2. 27.
  • MoonLake Immunotherapeutics Receives Endorsement from FDA and EMA for Phase 3 Program of Sonelokimab in Treating Hidradenitis Suppurativa MoonLake Immunotherapeutics Receives Endorsement from FDA and EMA for Phase 3 Program of Sonelokimab in Treating Hidradenitis Suppurativa MoonLake Immunotherapeutics, an innovative biopharmaceutical company, has received the green light from key health authorities—the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA)—for the advancement of their Phase 3 clinical tri.. 공감수 0 댓글수 0 2024. 2. 27.
  • BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062, Advancing Chronic Kidney Disease Treatment BioCity Biopharma Completes Enrollment for IgA Nephropathy Patients in Phase II Trial of SC0062 Advancing Chronic Kidney Disease Treatment Overview Company: BioCity Biopharma Indication: Chronic kidney disease (CKD), IgA nephropathy (IgAN), diabetic kidney disease (DKD) Drug: SC0062 Trial Phase: Phase 2 NCT ID: N/A Background Headquartered in Wuxi, China, BioCity Biopharma is steadfast in its de.. 공감수 0 댓글수 0 2024. 2. 27.
  • SSH 서버 보안 강화를 위한 기본적인 설정 방법 SSH 서버의 보안 강화에 대해 이야기해보려고 합니다. SSH는 Secure Shell의 약자로, 네트워크 상에서 암호화된 방식으로 원격 접속을 가능하게 하는 프로토콜입니다. 이 프로토콜을 사용하면, 물리적으로 멀리 떨어진 서버에 안전하게 접속할 수 있습니다. 그러나 이 SSH도 잘못 설정하거나 보안에 신경을 쓰지 않으면 공격의 대상이 될 수 있기 때문에 미리 주요 설정들을 알고 사용해야 합니다. 1. LoginGraceTime SSH 접속 시도 후 인증에 성공할 때까지 허용하는 시간을 줄입니다. 이를 통해 공격자가 무작위로 비밀번호를 시도하는 시간을 제한하게 됩니다. 기본 설정 값은 보통 2분이지만, 이를 1분으로 줄여줍니다. LoginGraceTime 1m 2. PermitRootLogin 루트 로그.. 공감수 0 댓글수 0 2023. 7. 31.
  • 해킹 방지를 위한 Nginx 설정 들어가며 웹 서버는 웹 애플리케이션을 호스팅하고 외부 요청을 처리하는 핵심적인 요소입니다. 하지만, 이는 공격자의 주요 공격 대상이기도 합니다. 이 글에서는, 웹 서버 보안을 강화하는 방법에 초점을 맞추어 설명하고자 합니다. 초보자들을 위해, 기본 원리와 함께 nginx 서버 설정을 통한 보안 강화 방법을 살펴보겠습니다. nginx 설정으로 보는 웹 서버 보안 nginx는 가장 널리 사용되는 오픈 소스 웹 서버 중 하나입니다. 웹 서버가 안전하게 운영되도록 하기 위해, nginx 설정 파일을 통해 다양한 보안 조치를 적용할 수 있습니다. 아래는 보안 강화를 위한 nginx 설정 파일의 예시입니다: server { server_name aaa.com; charset utf-8; #(1) add_header.. 공감수 0 댓글수 0 2023. 7. 31.
  • SSH 보안 강화, fail2ban 으로 알아보기 Fail2ban 이란? Fail2Ban은 잘못된 로그인 시도를 감지하고 이러한 시도를 차단하는 오픈 소스 소프트웨어입니다. 가장 흔한 사용 사례는 원격 서버에 SSH 접근을 시도하는 브루트포스 공격을 차단하는 것입니다. Fail2Ban은 다음과 같은 방식으로 작동합니다: 시스템 로그 파일을 모니터링하며, 미리 정의된 패턴(예를 들어, 잘못된 패스워드를 이용한 로그인 시도)에 맞는 행동을 감지합니다. 이러한 행동을 반복하는 IP 주소를 감지하면, 해당 IP 주소를 일정 시간 동안 차단합니다. 이 차단 기간은 사용자가 설정할 수 있습니다. 차단 기간이 끝나면 자동으로 해당 IP 주소의 차단을 해제합니다. 이런 방식으로, Fail2Ban은 악의적인 로그인 시도를 효과적으로 차단하고 서버를 보호합니다. SSH .. 공감수 0 댓글수 0 2023. 7. 30.
  • MindBio Therapeutics Begins Recruitment of Participants for World First LSD-Microdosing Clinical Trial in Cancer Patients Experiencing Emotional Distress MindBio Therapeutics Corp. has recently started recruiting participants for an innovative clinical trial that combines LSD microdosing with Meaning Centred Psychotherapy to help cancer patients experiencing emotional distress. This groundbreaking trial aims to address the mental health needs of advanced stage cancer patients, making it the first of its kind in the world. &nbsp The Phase 2 trial .. 공감수 0 댓글수 0 2023. 7. 26.
  • Intrommune Therapeutics Completes Last Patient Last Visit in Phase 1 OMEGA Study Intrommune Therapeutics, Inc., a clinical stage biotechnology company, has successfully completed the final visit of the last patient in the Phase 1 OMEGA Clinical Study for individuals with peanut allergy. This 48-week trial is specifically designed for adults with peanut allergies and aims to gather long-term safety data while determining the appropriate starting dose for INT301, an innovative.. 공감수 0 댓글수 0 2023. 7. 26.
  • Thermo Fisher Relies on CYBRA’s RFID Tracking and Alerting Capabilities to Keep Blood Cold ke-size="size16">&nbsp With the implementation of CYBRA's RFID tracking solution, Thermo Fisher was able to ensure the integrity and safety of their serum inventory. The system provided real-time monitoring of temperature conditions, ensuring that the sub-zero temperatures required for storage were maintained at all times. &nbsp In addition to temperature monitoring, the RFID solution also enabl.. 공감수 0 댓글수 0 2023. 7. 26.
  • Rosalind Franklin University Researcher Awarded NIH Funding to Investigate Links Between Down Syndrome and Alzheimer's Disease Rosalind Franklin University researcher, Dr. Grace E. Stutzmann, has been granted $1.8 million by the National Institute on Aging to investigate the connection between Down Syndrome and Alzheimer's disease. This research collaboration with New York University aims to develop new therapeutic strategies for individuals with Down Syndrome who are at risk of developing Alzheimer's. Down Syndrome is .. 공감수 0 댓글수 0 2023. 7. 26.
  • Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options Illumina, Inc. (NASDAQ: ILMN) and Pillar Biosciences Inc. have joined forces in a strategic partnership to expand the availability of Pillar's suite of oncology assays worldwide as part of Illumina's oncology product portfolio. The goal of this collaboration is to improve the efficiency, accuracy, and cost-effectiveness of oncology testing by utilizing advanced sequencing techniques, ultimately .. 공감수 0 댓글수 0 2023. 7. 26.
    문의안내
    • 티스토리
    • 로그인
    • 고객센터

    티스토리는 카카오에서 사랑을 담아 만듭니다.

    © Kakao Corp.